EU: Ball hires Goldman Sachs to sell 11 plants to appease antitrust regulators
US drinks can maker Ball Corp is ready to sell 11 European plants to get EU antitrust regulators to approve its $6.69 billion acquisition of Britain’s Rexam, people familiar with the matter said.
The world’s two largest beverage can makers by volume want to merge to better manage capital spending and cut costs. The European Commission, however, fears the deal would push up prices for companies and consumers.
The combined company would have 60 percent of the beverage can market in North America, 69 percent in Europe and 74 percent in Brazil, according to Morningstar analysts.
Ball is prepared to divest four factories in Germany, three in the UK, one each in Spain, France, the Netherlands and Austria, the sources said on Wednesday. Nine of the plants make cans and two of them can ends. The offer was submitted to the Commission last week.
Ball has said it is willing to sell more than $1.58 billion worth of assets to allay regulatory concerns. The company is also in discussions with antitrust authorities in the United States about assets it may have to divest in that country.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan